WILKES NSG 552 EXAM 1
PSYCHOPHARMACOLOGY QUESTIONS
AND CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| INSTANT DOWNLOAD PDF.
CORE DOMAINS
General Principles of Psychopharmacology
Pharmacokinetics and Pharmacodynamics
Neurotransmitters and Receptor Theory
Cytochrome P450 Enzymes and Drug Interactions
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs
Antipsychotics: First and Second Generation
Mood Stabilizers: Lithium, Valproate, Lamotrigine
Anxiolytics and Sedative-Hypnotics
INTRODUCTION
The Wilkes NSG 552 Psychopharmacology Examination 1 evaluates graduate-
level psychiatric-mental health nurse practitioner candidates for competence in
prescribing and monitoring psychopharmacological agents. The assessment
focuses on pharmacokinetic and pharmacodynamic principles,
neurotransmitter systems, receptor theory, and drug classification
mechanisms. Questions utilize multiple-choice and scenario-based formats
requiring application of neurobiological knowledge to clinical prescribing
,decisions. Emphasis is placed on cytochrome P450 interactions, adverse effect
recognition, and evidence-based medication selection for psychiatric disorders
across the lifespan.
SECTION ONE: QUESTIONS 1–100
1. A patient with schizophrenia is prescribed a first-generation
antipsychotic. The nurse practitioner explains that FGAs exert their
therapeutic effect primarily through which receptor mechanism?
A. 5-HT2A receptor antagonism
B. D2 receptor antagonism
C. D1 receptor agonism
D. GABA-A receptor positive allosteric modulation
B. D2 receptor antagonism
RATIONALE: First-generation antipsychotics exert their antipsychotic
effect primarily through potent D2 receptor antagonism in the mesolimbic
pathway, reducing positive symptoms of schizophrenia. 5-HT2A antagonism
is more characteristic of second-generation antipsychotics.
2. The nurse practitioner understands that the cytochrome P450
enzyme responsible for metabolizing approximately 25 percent of all
psychiatric medications is:
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
, B. CYP2D6
RATIONALE: CYP2D6 is a highly polymorphic enzyme that metabolizes
approximately 25 percent of psychiatric medications. Genetic variations can
lead to poor or ultrarapid metabolism, affecting drug efficacy and toxicity.
3. A patient is prescribed fluoxetine for major depressive disorder.
Which pharmacokinetic process describes the movement of fluoxetine
from the gastrointestinal tract into the systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
B. Absorption
RATIONALE: Absorption is the process by which a drug moves from its
site of administration into the bloodstream. This process is influenced by
lipid solubility and environmental pH, determining onset of action for
psychiatric medications.
4. In signal transduction, the enzyme responsible for the degradation
of cyclic adenosine monophosphate (cAMP) is:
A. Protein Kinase A
B. Adenylate Cyclase
C. Monoamine Oxidase
D. Phosphodiesterase
D. Phosphodiesterase
, RATIONALE: Phosphodiesterase breaks down second messengers like
cAMP to terminate a signal. Inhibiting this enzyme prolongs intracellular
effects of neurotransmitters, a mechanism central to several
psychopharmacological agents.
5. Which enzyme catalyzes the rate-limiting step in the synthesis of
serotonin from tryptophan?
A. Aromatic L-amino acid decarboxylase
B. Monoamine oxidase
C. Tryptophan hydroxylase
D. Catechol-O-methyltransferase
C. Tryptophan hydroxylase
RATIONALE: Tryptophan hydroxylase catalyzes the conversion of
tryptophan to 5-hydroxytryptophan (5-HTP), the rate-limiting step in
serotonin synthesis. Aromatic L-amino acid decarboxylase converts 5-HTP to
serotonin but is not rate-limiting.
6. A patient taking fluoxetine reports agitation and muscle twitching.
Which neurotransmitter system is most likely overstimulated?
A. Dopamine
B. Norepinephrine
C. GABA
D. Serotonin
D. Serotonin
PSYCHOPHARMACOLOGY QUESTIONS
AND CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| INSTANT DOWNLOAD PDF.
CORE DOMAINS
General Principles of Psychopharmacology
Pharmacokinetics and Pharmacodynamics
Neurotransmitters and Receptor Theory
Cytochrome P450 Enzymes and Drug Interactions
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs
Antipsychotics: First and Second Generation
Mood Stabilizers: Lithium, Valproate, Lamotrigine
Anxiolytics and Sedative-Hypnotics
INTRODUCTION
The Wilkes NSG 552 Psychopharmacology Examination 1 evaluates graduate-
level psychiatric-mental health nurse practitioner candidates for competence in
prescribing and monitoring psychopharmacological agents. The assessment
focuses on pharmacokinetic and pharmacodynamic principles,
neurotransmitter systems, receptor theory, and drug classification
mechanisms. Questions utilize multiple-choice and scenario-based formats
requiring application of neurobiological knowledge to clinical prescribing
,decisions. Emphasis is placed on cytochrome P450 interactions, adverse effect
recognition, and evidence-based medication selection for psychiatric disorders
across the lifespan.
SECTION ONE: QUESTIONS 1–100
1. A patient with schizophrenia is prescribed a first-generation
antipsychotic. The nurse practitioner explains that FGAs exert their
therapeutic effect primarily through which receptor mechanism?
A. 5-HT2A receptor antagonism
B. D2 receptor antagonism
C. D1 receptor agonism
D. GABA-A receptor positive allosteric modulation
B. D2 receptor antagonism
RATIONALE: First-generation antipsychotics exert their antipsychotic
effect primarily through potent D2 receptor antagonism in the mesolimbic
pathway, reducing positive symptoms of schizophrenia. 5-HT2A antagonism
is more characteristic of second-generation antipsychotics.
2. The nurse practitioner understands that the cytochrome P450
enzyme responsible for metabolizing approximately 25 percent of all
psychiatric medications is:
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19
, B. CYP2D6
RATIONALE: CYP2D6 is a highly polymorphic enzyme that metabolizes
approximately 25 percent of psychiatric medications. Genetic variations can
lead to poor or ultrarapid metabolism, affecting drug efficacy and toxicity.
3. A patient is prescribed fluoxetine for major depressive disorder.
Which pharmacokinetic process describes the movement of fluoxetine
from the gastrointestinal tract into the systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
B. Absorption
RATIONALE: Absorption is the process by which a drug moves from its
site of administration into the bloodstream. This process is influenced by
lipid solubility and environmental pH, determining onset of action for
psychiatric medications.
4. In signal transduction, the enzyme responsible for the degradation
of cyclic adenosine monophosphate (cAMP) is:
A. Protein Kinase A
B. Adenylate Cyclase
C. Monoamine Oxidase
D. Phosphodiesterase
D. Phosphodiesterase
, RATIONALE: Phosphodiesterase breaks down second messengers like
cAMP to terminate a signal. Inhibiting this enzyme prolongs intracellular
effects of neurotransmitters, a mechanism central to several
psychopharmacological agents.
5. Which enzyme catalyzes the rate-limiting step in the synthesis of
serotonin from tryptophan?
A. Aromatic L-amino acid decarboxylase
B. Monoamine oxidase
C. Tryptophan hydroxylase
D. Catechol-O-methyltransferase
C. Tryptophan hydroxylase
RATIONALE: Tryptophan hydroxylase catalyzes the conversion of
tryptophan to 5-hydroxytryptophan (5-HTP), the rate-limiting step in
serotonin synthesis. Aromatic L-amino acid decarboxylase converts 5-HTP to
serotonin but is not rate-limiting.
6. A patient taking fluoxetine reports agitation and muscle twitching.
Which neurotransmitter system is most likely overstimulated?
A. Dopamine
B. Norepinephrine
C. GABA
D. Serotonin
D. Serotonin
